摘要
目的探讨固本扶正汤对宫颈癌化疗患者转移抑制基因(KISS-1)蛋白及Th1/Th2平衡影响。方法便利选取2019年8月—2021年8月北大荒集团总医院收治的宫颈癌患者92例,随机分为对照组(n=46)和观察组(n=46)。对照组行常规化疗,观察组在化疗同时给予固本扶正汤治疗。对比两组治疗疗效、KISS-1蛋白及血清Th1/Th2相关因子水平。结果观察组治疗有效率(82.61%)高于对照组(63.04%),差异有统计学意义(χ^(2)=4.449,P<0.05)。治疗后,观察组KISS-1蛋白阳性表达率、血清IFN-γ、IL-2水平高于对照组,IL-4低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论固本扶正汤对宫颈癌化疗患者的治疗疗效确切,可促进KISS-1蛋白表达增加,改善细胞免疫水平,并可减少不良反应发生,值得临床进一步推广。
Objective To investigate the effect of Guben Fuzheng decoction on the protein of metastasis suppressor gene(KISS-1)and the balance of Th1/Th2 in patients with cervical cancer undergoing chemotherapy.Methods A total of 92 cervical cancer patients admitted to Beidahuang Group General Hospital from August 2019 to August 2021 were conveniently selected and randomly divided into control group(n=46)and observation group(n=46).The control group was given conventional chemotherapy,while the observation group was given Guben Fuzheng Decoction at the same time of chemotherapy.The therapeutic efficacy,KISS-1 protein and serum Th1/Th2-related factor levels were compared between the two groups.Results The effective rate of treatment in the observation group(82.61%)was higher than that in the control group(63.04%),the difference was statistically significant(χ^(2)=4.449,P<0.05).After treatment,the positive expression rate of KISS-1 protein,serum IFN-γand IL-2 levels in the observation group were higher than those in the control group,and IL-4 was lower than that in the control group,the difference was statistically significant(P<0.05).The incidences of adverse reactions such as leukopenia in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).Conclusion Guben Fuzheng Decoction has definite curative effect on patients with cervical cancer chemotherapy,can promote the increase of KISS-1 protein expression,improve the level of cellular immunity,and reduce the occurrence of adverse reactions,which is worthy of further clinical promotion.
作者
宋洪杰
SONG Hongjie(Department of Oncology,Beidahuang Group General Hospital,Harbin,Heilongjiang Province,150088 China)
出处
《中外医疗》
2022年第17期9-12,25,共5页
China & Foreign Medical Treatment
